Hereditary Optic Atrophies Market

Market Overview:

The 7 major hereditary optic atrophies markets are expected to exhibit a CAGR of 4.38% during 2024-2034.

The hereditary optic atrophies market has been comprehensively analyzed in IMARC's new report titled "Hereditary Optic Atrophies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hereditary optic atrophies (HOAs) encompass a group of rare genetic disorders characterized by the progressive degeneration of the optic nerve, which links the eye to the brain. This condition is primarily inherited through a family's genetic lineage and can manifest in various ways, making early diagnosis crucial. The symptoms of HOAs typically emerge gradually and often include a gradual loss of central and peripheral vision, decreased visual acuity, color vision impairment, and sometimes the development of a pale or waxy appearance to the optic nerve head during an eye examination. Individuals suffering from this illness may also experience indications, such as difficulty with contrast sensitivity and challenges with tasks requiring fine visual discrimination. The diagnosis of HOAs involves a thorough medical history review, a comprehensive eye examination, and specialized tests like visual field testing, optical coherence tomography (OCT), and genetic testing to identify the specific mutation responsible for the condition.

The escalating prevalence of mutations in genes like OPA1 and WFS1, which lead to the degeneration of optic nerves and affect vision, is primarily driving the hereditary optic atrophies market. In addition to this, the inflating utilization of potent medications, including antioxidants and neuroprotective agents, aimed at slowing down the rate of vision loss and enhancing mitochondrial function, is also creating a positive outlook for the market. Moreover, the widespread adoption of rehabilitative measures like low vision aids and orientation mobility training, designed to help individuals suffering from HOAs adapt to vision loss and improve their quality of life, is further bolstering the market growth. Apart from this, the rising usage of stem cell therapy and gene therapy, since they focus on replacing or repairing the defective genetic material responsible for optic nerve degeneration, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bioinformatics, which can offer more precise genetic testing, thereby allowing for the identification of gene mutations and enabling targeted therapies, is also augmenting the market growth. Furthermore, the increasing application of optogenetics, a cutting-edge field that involves the use of light-sensitive proteins to restore vision by stimulating retinal cells, is expected to drive the hereditary optic atrophies market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hereditary optic atrophies market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hereditary optic atrophies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hereditary optic atrophies market in any manner.

Recent Developments:

• In August 2023, Neurophth Therapeutics stated that the first patient had been dosed in the international Phase I/II clinical study for the treatment of Leber hereditary optic neuropathy caused by the ND1 mutation (ND1-LHON).

Key Highlights:

• In Finland and northeastern England, LHON affects around one in 30,000 to 50,000 persons.
• The prevalence of vision loss due to LHON is roughly 1:50,000 persons.
• It has a high male prevalence (80% to 90%), and the average age at onset is between 15 and 35 years.
• Most carriers never have major visual loss; however, males are four to five times more likely than females to lose vision and become impacted.
• The most common type of hereditary optic neuropathy is dominant optic atrophy (DOA), which is estimated to affect 1 in 10,000 to 1 in 50,000 individuals.

Drugs:

Raxone(Idebenone) is a drug used for the treatment of visual impairment in adults and adolescents 12 and older with LHON. Idebenone is the active component of Raxone. Idebenone promotes energy generation by restoring mitochondrial activity, while limiting the cellular damage and vision loss found in LHON.

GS010 targets LHON by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform developed at the Institut de la Vision in Paris. When associated with the gene of interest, the platform can specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transported into the cell and expressed, resulting in the production of a functional protein that is subsequently shuttled to the mitochondria via specific nucleotidic sequences to restore absent or defective mitochondrial function.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hereditary optic atrophies market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hereditary optic atrophies market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hereditary optic atrophies marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hereditary optic atrophies market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hereditary optic atrophies market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hereditary optic atrophies market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hereditary optic atrophies across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hereditary optic atrophies by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hereditary optic atrophies across the seven major markets?
• What is the size of the hereditary optic atrophies patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hereditary optic atrophies?
• What will be the growth rate of patients across the seven major markets?
   

Hereditary Optic Atrophies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hereditary optic atrophies drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hereditary optic atrophies market?
• What are the key regulatory events related to the hereditary optic atrophies market?
• What is the structure of clinical trial landscape by status related to the hereditary optic atrophies market?
• What is the structure of clinical trial landscape by phase related to the hereditary optic atrophies market?
• What is the structure of clinical trial landscape by route of administration related to the hereditary optic atrophies market?